United Immunity is a biotech company that focuses on innovative drug delivery systems utilizing polysaccharide pullulan-based nanoparticles, specifically Pullulan Nanoparticles (PNP) and Pullulan-coated Lipid Nanoparticles (P-LNP). These technologies are designed to selectively deliver therapeutic agents to myeloid cells, such as macrophages and dendritic cells, which play crucial roles in the immune response. The Myeloid Targeting Platform™ leverages the specific binding of pullulan to the receptor DC-SIGN (CD209) expressed on these cells, enabling targeted delivery of various therapeutic compounds, including low molecular weight compounds, peptides, proteins, and nucleic acids like mRNA and siRNA. This targeted approach aims to enhance the efficacy of treatments for diseases such as cancer, infections, autoimmune disorders, and metabolic diseases.

The PNP and P-LNP systems are characterized by their biocompatibility and low immunogenicity, allowing for repeated administration without significant adverse effects. PNP is particularly effective for delivering small molecules and proteins, while P-LNP is optimized for nucleic acid delivery. The ability to selectively target myeloid cells in lymphoid organs and tumor microenvironments positions these nanoparticles as promising tools for developing next-generation vaccines and therapies. The company’s research indicates that these delivery systems can significantly improve immune responses, particularly in the context of cancer immunotherapy and infectious disease vaccines, by facilitating the efficient presentation of antigens to T cells and enhancing the overall therapeutic outcome.

Japan

We will create immunotherapy using nanotechnology as a new treatment option for intractable cancers and viral infections.Uniting Immunity and Nanotechnology for Fighting Cancer and Infectious Diseases

United Immunity

Company Details